Physician profile
Jason Ro
NPI 1538784772
$1,300.19
in general payments reported to CMS, 2019-2025
15 companies · $658 in 2025
The $658 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.99 · 2021: $76.24 · 2022: $43.05 · 2023: $175 · 2024: $335 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $282.18 | 2023-2025 | Miebo, Eureka, Xiidra |
| Sun Pharmaceutical Industries INC. | $192.81 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $175.29 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $155.82 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $107.64 | 2023-2024 | |
| Glaukos Corporation | $76.99 | 2024-2025 | Idose, Photrexa Viscous and Photrexa |
| Abbvie INC. | $66.00 | 2024 | |
| Alcon Vision LLC | $57.41 | 2024-2025 | Rocklatan, Hydrus Microstent |
| Harrow Eye, LLC | $56.41 | 2025 | Vevye |
| Dompe US, INC. | $32.37 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $31.02 | 2021 | |
| Rxsight INC | $24.56 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.78 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.99 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.